天域生物科技股份有限公司关于2025年第三季度报告的更正公告

Core Viewpoint - The correction of the Q3 2025 report by Tianyu Biotechnology Co., Ltd. does not affect the company's overall financial performance or key financial metrics, ensuring the accuracy of financial data and disclosures [2][3][4]. Summary by Sections Correction Details - The correction involves adjustments to earnings per share, return on equity, and reclassification between long-term loans and current liabilities, but does not impact total assets, total liabilities, equity, revenue, or net profit [2][3]. - The company confirmed that the asset-liability ratio remains unchanged and that the correction will not affect the operating performance for the first three quarters of 2025 [2][3]. Review Process - The Audit Committee approved the correction on November 21, 2025, stating that it complies with relevant laws and regulations, and reflects the company's financial status more accurately [3]. - The Board of Directors also approved the correction, affirming that it aligns with the actual financial situation and relevant disclosure rules, with no impact on the asset and equity reporting, total liabilities, or cash flow statement [3]. Additional Notes - Other contents of the Q3 2025 report remain unchanged, and the corrected report will be disclosed on the Shanghai Stock Exchange's official website [4]. - The company expressed apologies for any inconvenience caused to investors and committed to enhancing the training of financial personnel and improving internal control mechanisms for financial data and disclosures [4].